Global Thyroid Gland Disorders Treatment Market Research Report (2025–2036)
Western Market Research predicts that the Global Thyroid Gland Disorders Treatment Market was valued at USD 4.15 Billion in 2025 and is expected to reach USD 7.22 Billion by the year 2036, growing at a CAGR of 5.15% globally during the forecast period.
1. Global Thyroid Gland Disorders Treatment Market Overview
The thyroid gland disorders treatment market is a mature yet steadily expanding sector of the global pharmaceutical industry. The market encompasses therapies for a range of conditions, primarily hypothyroidism and hyperthyroidism, but increasingly focuses on thyroid eye disease (TED) and thyroid cancer.
This research study utilizes high-precision modeling and extensive primary data from endocrinologists and supply chain experts. By evaluating historical performance from 2020–2024, the report provides a comprehensive outlook for 2026–2036, factoring in the rising prevalence of autoimmune diseases like Hashimoto’s thyroiditis and Graves' disease, alongside advancements in personalized hormone dosing.
2. Impact of COVID-19 on Thyroid Gland Disorders Treatment Market
The COVID-19 pandemic significantly affected the thyroid treatment market in 2020. Beyond initial logistical disruptions, clinical evidence emerged suggesting a link between SARS-CoV-2 infection and subacute thyroiditis or the exacerbation of pre-existing thyroid conditions. This "post-viral thyroiditis" led to a surge in diagnostic screenings in late 2021 and 2022. Additionally, the pandemic accelerated the adoption of telehealth for chronic disease management, which has since become a permanent fixture in thyroid care.
3. Market Segmentation
By Disorder Type:
-
Hypothyroidism: The largest segment, driven by the lifelong need for hormone replacement therapy (HRT).
-
Hyperthyroidism: Focus on antithyroid medications and radioactive iodine.
-
Thyroid Eye Disease (TED): A high-growth segment following the approval of specific biologics.
-
Thyroid Cancer: Targeted therapies and radioactive iodine ablation.
By Drug Class (New Segment):
-
Thyroid Hormone Replacement Drugs: Levothyroxine (dominant), Liothyronine.
-
Antithyroid Medicinal Products: Methimazole, Propylthiouracil.
-
Biologics: Teprotumumab (for TED).
-
Iodine-based Therapies: Radioactive Iodine-131.
By Route of Administration (New Segment):
-
Oral: Capsules and tablets (standard for daily maintenance).
-
Intravenous/Injectable: Primarily for thyroid crisis (Storm) or biological therapies.
-
Liquid Formulations: Growing segment for pediatric and geriatric patients with swallowing difficulties.
By Application (Distribution Channel):
-
Hospital Pharmacies: Central for acute cases and radioactive iodine treatments.
-
Retail Pharmacies: Dominant for monthly maintenance prescriptions.
-
Online Pharmacies: Fastest-growing channel due to the long-term, recurring nature of thyroid medication.
4. Top Key Players Covered
-
AbbVie Inc. (Synthroid)
-
Pfizer Inc.
-
Merck KGaA
-
Novartis International AG
-
Abbott Laboratories
-
Sanofi
-
GlaxoSmithKline (GSK)
-
Takeda Pharmaceutical Company Limited
-
Horizon Therapeutics (Amgen)
-
Acella Pharmaceuticals, LLC
-
Jerome Stevens Pharmaceuticals, Inc.
-
Mylan N.V. (Viatris)
-
Lannett Company, Inc.
-
IBSA Institut Biochimique SA
5. Regional Analysis
-
North America: Holds the largest market share due to high awareness, expensive treatment options (biologics), and a robust clinical pipeline.
-
Europe: Second-largest market; growth is driven by the high prevalence of Hashimoto’s thyroiditis and advanced healthcare systems in Germany and France.
-
Asia-Pacific: The fastest-growing region. Increasing screenings in China and India, coupled with large populations and rising disposable income, are primary drivers.
-
South America: Growth driven by improvements in healthcare access in Brazil and Argentina.
-
Middle East & Africa: Driven by government initiatives to modernize healthcare and treat hormonal imbalances in the GCC countries.
6. Porter’s Five Forces Analysis
-
Threat of New Entrants (Low): High regulatory barriers for hormonal drugs and the dominance of well-established generic versions act as deterrents.
-
Bargaining Power of Buyers (High): Consumers and insurance payers have high power due to the abundance of generic levothyroxine options.
-
Bargaining Power of Suppliers (Medium): Limited number of high-quality API (Active Pharmaceutical Ingredient) suppliers for synthetic hormones.
-
Threat of Substitutes (Low): There are no non-drug substitutes for essential thyroid hormone replacement.
-
Competitive Rivalry (High): Intense price competition among generic manufacturers, while branded players focus on "purity" and "bioavailability."
7. SWOT Analysis
-
Strengths: Inelastic demand for maintenance therapy; high patient adherence.
-
Weaknesses: Thin margins on generic medications; strict storage requirements (light/temperature sensitivity).
-
Opportunities: Expansion into liquid and soft-gel formulations; growth in biological treatments for autoimmune thyroid eye disease.
-
Threats: Pricing caps in various jurisdictions; long-term generic erosion of branded products.
8. Trend Analysis
-
The "Clean Label" Trend: Increasing demand for thyroid medications free from dyes, lactose, and gluten for sensitive patients.
-
Precision Dosing: Innovations in blood-testing kits that allow for micro-adjustments in levothyroxine dosing.
-
Liquid Levothyroxine: Significant shift in the pediatric and geriatric markets toward liquid formulations for better absorption and ease of use.
9. Drivers & Challenges
-
Drivers:
-
Rising global prevalence of thyroid disorders, particularly among women.
-
Increase in early diagnostic screenings through routine health check-ups.
-
Aging population prone to metabolic and hormonal issues.
-
-
Challenges:
-
High rate of misdiagnosis or overlapping symptoms with other conditions.
-
Narrow Therapeutic Index (NTI): Small changes in dose can lead to toxicity or treatment failure, complicating generic switching.
-
10. Value Chain Analysis
-
R&D: Focus on improving drug delivery and minimizing excipient interference.
-
API Sourcing: Synthetic manufacturing of T3 and T4 hormones.
-
Manufacturing: High-precision tableting or liquid filling to ensure dose consistency.
-
Distribution: Use of specialized cold-chain or light-protected logistics.
-
Retail/Dispensing: Pharmacies providing monthly maintenance doses.
-
End-User: Patients requiring lifelong hormone titration.
11. Quick Recommendations for Stakeholders
-
For Manufacturers: Invest in soft-gel and liquid formulations to differentiate from the saturated generic tablet market.
-
For Investors: Focus on companies developing biologics for Graves' disease and TED, as these represent the high-margin frontier of the market.
-
For Healthcare Providers: Prioritize patient education regarding consistent drug timing and avoiding interactions with calcium or iron supplements.
-
For Retailers: Develop automatic refill programs to capitalize on the chronic, lifelong nature of the disease.
1. Market Overview of Thyroid Gland Disorders Treatment
1.1 Thyroid Gland Disorders Treatment Market Overview
1.1.1 Thyroid Gland Disorders Treatment Product Scope
1.1.2 Market Status and Outlook
1.2 Thyroid Gland Disorders Treatment Market Size by Regions: 2015 VS 2021 VS 2026
1.3 Thyroid Gland Disorders Treatment Historic Market Size by Regions
1.4 Thyroid Gland Disorders Treatment Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Thyroid Gland Disorders Treatment Sales Market by Type
2.1 Global Thyroid Gland Disorders Treatment Historic Market Size by Type
2.2 Global Thyroid Gland Disorders Treatment Forecasted Market Size by Type
2.3 Hypothyroidism
2.4 Hyperthyroidism
3. Covid-19 Impact Thyroid Gland Disorders Treatment Sales Market by Application
3.1 Global Thyroid Gland Disorders Treatment Historic Market Size by Application
3.2 Global Thyroid Gland Disorders Treatment Forecasted Market Size by Application
3.3 Hospitals
3.4 Clinics
3.5 Others
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Thyroid Gland Disorders Treatment Production Capacity Market Share by Manufacturers
4.2 Global Thyroid Gland Disorders Treatment Revenue Market Share by Manufacturers
4.3 Global Thyroid Gland Disorders Treatment Average Price by Manufacturers
5. Company Profiles and Key Figures in Thyroid Gland Disorders Treatment Business
5.1 GlaxoSmithKline
5.1.1 GlaxoSmithKline Company Profile
5.1.2 GlaxoSmithKline Thyroid Gland Disorders Treatment Product Specification
5.1.3 GlaxoSmithKline Thyroid Gland Disorders Treatment Production Capacity, Revenue, Price and Gross Margin
5.2 Pfizer
5.2.1 Pfizer Company Profile
5.2.2 Pfizer Thyroid Gland Disorders Treatment Product Specification
5.2.3 Pfizer Thyroid Gland Disorders Treatment Production Capacity, Revenue, Price and Gross Margin
5.3 Inc
5.3.1 Inc Company Profile
5.3.2 Inc Thyroid Gland Disorders Treatment Product Specification
5.3.3 Inc Thyroid Gland Disorders Treatment Production Capacity, Revenue, Price and Gross Margin
5.4 Novartis International AG
5.4.1 Novartis International AG Company Profile
5.4.2 Novartis International AG Thyroid Gland Disorders Treatment Product Specification
5.4.3 Novartis International AG Thyroid Gland Disorders Treatment Production Capacity, Revenue, Price and Gross Margin
5.5 Abbott Laboratories
5.5.1 Abbott Laboratories Company Profile
5.5.2 Abbott Laboratories Thyroid Gland Disorders Treatment Product Specification
5.5.3 Abbott Laboratories Thyroid Gland Disorders Treatment Production Capacity, Revenue, Price and Gross Margin
5.6 AbbVie
5.6.1 AbbVie Company Profile
5.6.2 AbbVie Thyroid Gland Disorders Treatment Product Specification
5.6.3 AbbVie Thyroid Gland Disorders Treatment Production Capacity, Revenue, Price and Gross Margin
5.7 Inc
5.7.1 Inc Company Profile
5.7.2 Inc Thyroid Gland Disorders Treatment Product Specification
5.7.3 Inc Thyroid Gland Disorders Treatment Production Capacity, Revenue, Price and Gross Margin
5.8 Sanofi
5.8.1 Sanofi Company Profile
5.8.2 Sanofi Thyroid Gland Disorders Treatment Product Specification
5.8.3 Sanofi Thyroid Gland Disorders Treatment Production Capacity, Revenue, Price and Gross Margin
5.9 Takeda Pharmaceutical
5.9.1 Takeda Pharmaceutical Company Profile
5.9.2 Takeda Pharmaceutical Thyroid Gland Disorders Treatment Product Specification
5.9.3 Takeda Pharmaceutical Thyroid Gland Disorders Treatment Production Capacity, Revenue, Price and Gross Margin
5.10 Allergan Plc
5.10.1 Allergan Plc Company Profile
5.10.2 Allergan Plc Thyroid Gland Disorders Treatment Product Specification
5.10.3 Allergan Plc Thyroid Gland Disorders Treatment Production Capacity, Revenue, Price and Gross Margin
5.11 Merck KGaA
5.11.1 Merck KGaA Company Profile
5.11.2 Merck KGaA Thyroid Gland Disorders Treatment Product Specification
5.11.3 Merck KGaA Thyroid Gland Disorders Treatment Production Capacity, Revenue, Price and Gross Margin
5.12 Lannett Company
5.12.1 Lannett Company Company Profile
5.12.2 Lannett Company Thyroid Gland Disorders Treatment Product Specification
5.12.3 Lannett Company Thyroid Gland Disorders Treatment Production Capacity, Revenue, Price and Gross Margin
5.13 Inc
5.13.1 Inc Company Profile
5.13.2 Inc Thyroid Gland Disorders Treatment Product Specification
5.13.3 Inc Thyroid Gland Disorders Treatment Production Capacity, Revenue, Price and Gross Margin
5.14 Mylan N.V
5.14.1 Mylan N.V Company Profile
5.14.2 Mylan N.V Thyroid Gland Disorders Treatment Product Specification
5.14.3 Mylan N.V Thyroid Gland Disorders Treatment Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America Thyroid Gland Disorders Treatment Market Size
6.2 North America Thyroid Gland Disorders Treatment Key Players in North America
6.3 North America Thyroid Gland Disorders Treatment Market Size by Type
6.4 North America Thyroid Gland Disorders Treatment Market Size by Application
7. East Asia
7.1 East Asia Thyroid Gland Disorders Treatment Market Size
7.2 East Asia Thyroid Gland Disorders Treatment Key Players in North America
7.3 East Asia Thyroid Gland Disorders Treatment Market Size by Type
7.4 East Asia Thyroid Gland Disorders Treatment Market Size by Application
8. Europe
8.1 Europe Thyroid Gland Disorders Treatment Market Size
8.2 Europe Thyroid Gland Disorders Treatment Key Players in North America
8.3 Europe Thyroid Gland Disorders Treatment Market Size by Type
8.4 Europe Thyroid Gland Disorders Treatment Market Size by Application
9. South Asia
9.1 South Asia Thyroid Gland Disorders Treatment Market Size
9.2 South Asia Thyroid Gland Disorders Treatment Key Players in North America
9.3 South Asia Thyroid Gland Disorders Treatment Market Size by Type
9.4 South Asia Thyroid Gland Disorders Treatment Market Size by Application
10. Southeast Asia
10.1 Southeast Asia Thyroid Gland Disorders Treatment Market Size
10.2 Southeast Asia Thyroid Gland Disorders Treatment Key Players in North America
10.3 Southeast Asia Thyroid Gland Disorders Treatment Market Size by Type
10.4 Southeast Asia Thyroid Gland Disorders Treatment Market Size by Application
11. Middle East
11.1 Middle East Thyroid Gland Disorders Treatment Market Size
11.2 Middle East Thyroid Gland Disorders Treatment Key Players in North America
11.3 Middle East Thyroid Gland Disorders Treatment Market Size by Type
11.4 Middle East Thyroid Gland Disorders Treatment Market Size by Application
12. Africa
12.1 Africa Thyroid Gland Disorders Treatment Market Size
12.2 Africa Thyroid Gland Disorders Treatment Key Players in North America
12.3 Africa Thyroid Gland Disorders Treatment Market Size by Type
12.4 Africa Thyroid Gland Disorders Treatment Market Size by Application
13. Oceania
13.1 Oceania Thyroid Gland Disorders Treatment Market Size
13.2 Oceania Thyroid Gland Disorders Treatment Key Players in North America
13.3 Oceania Thyroid Gland Disorders Treatment Market Size by Type
13.4 Oceania Thyroid Gland Disorders Treatment Market Size by Application
14. South America
14.1 South America Thyroid Gland Disorders Treatment Market Size
14.2 South America Thyroid Gland Disorders Treatment Key Players in North America
14.3 South America Thyroid Gland Disorders Treatment Market Size by Type
14.4 South America Thyroid Gland Disorders Treatment Market Size by Application
15. Rest of the World
15.1 Rest of the World Thyroid Gland Disorders Treatment Market Size
15.2 Rest of the World Thyroid Gland Disorders Treatment Key Players in North America
15.3 Rest of the World Thyroid Gland Disorders Treatment Market Size by Type
15.4 Rest of the World Thyroid Gland Disorders Treatment Market Size by Application
16 Thyroid Gland Disorders Treatment Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter
Market Segmentation
By Disorder Type:
-
Hypothyroidism: The largest segment, driven by the lifelong need for hormone replacement therapy (HRT).
-
Hyperthyroidism: Focus on antithyroid medications and radioactive iodine.
-
Thyroid Eye Disease (TED): A high-growth segment following the approval of specific biologics.
-
Thyroid Cancer: Targeted therapies and radioactive iodine ablation.
By Drug Class (New Segment):
-
Thyroid Hormone Replacement Drugs: Levothyroxine (dominant), Liothyronine.
-
Antithyroid Medicinal Products: Methimazole, Propylthiouracil.
-
Biologics: Teprotumumab (for TED).
-
Iodine-based Therapies: Radioactive Iodine-131.
By Route of Administration (New Segment):
-
Oral: Capsules and tablets (standard for daily maintenance).
-
Intravenous/Injectable: Primarily for thyroid crisis (Storm) or biological therapies.
-
Liquid Formulations: Growing segment for pediatric and geriatric patients with swallowing difficulties.
By Application (Distribution Channel):
-
Hospital Pharmacies: Central for acute cases and radioactive iodine treatments.
-
Retail Pharmacies: Dominant for monthly maintenance prescriptions.
-
Online Pharmacies: Fastest-growing channel due to the long-term, recurring nature of thyroid medication.
4. Top Key Players Covered
-
AbbVie Inc. (Synthroid)
-
Pfizer Inc.
-
Merck KGaA
-
Novartis International AG
-
Abbott Laboratories
-
Sanofi
-
GlaxoSmithKline (GSK)
-
Takeda Pharmaceutical Company Limited
-
Horizon Therapeutics (Amgen)
